Humacyte

Humacyte Humacyte produces life-sustaining, human bioengineered blood vessels and tissues designed to remodel with the patient's own cells.

05/26/2026

In the U.S., someone has a stroke every 40 seconds.1 The CDC also reports the 2023 stroke death rate was 39.0 per 100,000, underscoring why recognition and response matter. 1, 2

Know the warning signs (B.E. F.A.S.T.)2:

• Balance loss • Eye/vision changes • Face drooping • Arm weakness • Speech difficulty • Time to call 911

The CDC notes that people who arrive at the ER within 3 hours of first symptoms often have less disability months later than those who receive delayed care.1

At Humacyte, we’re proud to support vascular innovation to offer new solutions and help improve patient care.

Learn more about Humacyte and our groundbreaking science and innovations at https://humacyte.com

References:
1. Centers for Disease Control and Prevention. Stroke facts. Updated October 24, 2024. Accessed May 2026. https://www.cdc.gov/stroke/data-research/facts-stats/index.html [cdc.gov]
2. American Stroke Association. Stroke symptoms and warning signs. Accessed May 2026. https://www.stroke.org/en/about-stroke/stroke-symptoms [mcknights.com]

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

Join Humacyte TODAY at The Vascular Access Society of the Americas (VASA) for a scientific presentation examining the pe...
05/21/2026

Join Humacyte TODAY at The Vascular Access Society of the Americas (VASA) for a scientific presentation examining the performance of Acellular Tissue Engineered Vessels (ATEV) following repeated cannulation for dialysis access.

This talk will highlight research about ATEVs—offering insight into bioengineered conduits and vascular access durability.

VASA Annual Meeting
5:16–5:23 PM
Speakers: Maisha Clancy, MA; Juan Wang, PhD

Humacyte is a trademark and property of Humacyte Global, Inc. All other trademarks are the property of their respective owners.

© 2026 Humacyte Global Inc. All Rights Reserved.

On Trauma Survivors Day, May 20th, we honor the strength and resilience of trauma survivors—and the clinicians, caregive...
05/20/2026

On Trauma Survivors Day, May 20th, we honor the strength and resilience of trauma survivors—and the clinicians, caregivers, and first responders who support recovery when it matters most. Every person involved and tool used to save lives and improve recovery is critical in the healing journey.

At Humacyte, we are incredibly proud to advance Symvess® acellular tissue engineered vessel-tyod (ATEV), a human derived bioengineered vessel developed to support urgent arterial injury repair.

We remain focused on innovation in emergency care. Our clinical data includes civilian use in the United States and Israel, and real world military applications during the war in Ukraine where urgent vascular reconstruction can make a difference between limb salvage and loss. Research and clinical experience are critical and have helped expand understanding of how innovative vascular solutions may support limb salvage and recovery after severe injuries.

Today, we recognize survivors—and reaffirm our commitment to advancing care that supports healing after trauma.

WATCH Devin’s Story, a real patient and ATEV recipient, by SCROLLING TO THE BOTTOM of the page of page at Symvess.com.

CLICK HERE>>> https://www.symvess.com

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING,
AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE- Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000346

05/19/2026

As we continue to recognize American Stroke Awareness Month, we’re sharing a reminder of how central vascular health is across all cardiovascular care.

In the United States, cardiovascular disease remains the leading cause of death, accounting for nearly one in every three deaths nationwide.¹

Each year, hundreds of thousands of people undergo cardiac procedures to restore or support blood flow—underscoring the critical role of healthy, reliable vasculature throughout care.

Adult cardiac surgery is tracked at remarkable scale through the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database, one of the most comprehensive clinical registries in medicine.² The STS Database includes more than nine million procedures, capturing the vast majority of adult cardiac surgeries performed in the U.S.² In the most recent fully reported year (2022), the database captured 278,202 adult cardiac surgery procedures.²

Together, these data reinforce why vascular health is foundational not only to stroke prevention and response, but also to cardiac surgery, trauma care, and complex vascular intervention.

At Humacyte, we are deeply focused on vascular health—and on advancing regenerative innovations designed to support blood flow where it matters most, across trauma and complex vascular care.

Learn more about Humacyte and our groundbreaking science https://humacyte.com

References
1. Centers for Disease Control and Prevention. Heart Disease Facts. Updated October 24, 2024. Accessed May 2026. https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html [cdc.gov]

2. Wyler von Ballmoos MC, Kaneko T, Iribarne A, et al. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2023 update on procedure data and research. Ann Thorac Surg. 2024;117(2):260 270. doi:10.1016/j.athoracsur.2023.11.016 [annalsthor...urgery.org]

Trademarks are property of Humacyte Global, Inc.
© 2026 Humacyte Global Inc. All Rights Reserved.

This National Women's Health Week, we are looking back at the foundation of our company.20+ years ago, Humacyte was born...
05/15/2026

This National Women's Health Week, we are looking back at the foundation of our company.

20+ years ago, Humacyte was born from the vision of three women - scientists and pioneers who believed that regenerative medicine could redefine the future of vascular surgery. Dr. Laura Niklason, Dr. Shannon Dahl, Dr. Juliana Blum set out to solve one of medicine's most enduring challenges: providing a reliable, off-the- shelf biologic conduit that becomes the patient's own tissue.

Two decades later, the vision is a commercial reality with the launch of Symvess® acellular tissue engineered vessel-tyod for extremity vascular injury. As a female founded company, we remain dedicated to the pursuit of scientific excellence and the improvement of patient outcomes across the vascular journey.

We celebrate the women in our labs, our offices, and the operating rooms who continue to push the boundaries of what is possible in biotechnology.

Learn more at https://humacyte.com

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING,
AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

05/14/2026

May is American Stroke Awareness Month.

Stroke is a vascular emergency — and the numbers make the mission clear.
• More than 795,000 people in the U.S. have a stroke each year, and ~87% are ischemic (blocked blood flow).1
• The CDC reports a 2023 stroke death rate of 39.0 per 100,000 (down slightly from 2022). 1,2

Because stroke is so closely tied to blood flow, it’s also strongly linked to vascular risk factors such as high blood pressure, high cholesterol, smoking, obesity, and diabetes. 1

This May, we join clinicians, researchers, and patients in advancing awareness during American Stroke Awareness Month.

Learn more about Humacyte and our groundbreaking science in vascular care at https://humacyte.com

References:
1. Centers for Disease Control and Prevention. Stroke facts. Updated October 24, 2024. Accessed May 2026. https://www.cdc.gov/stroke/data-research/facts-stats/index.html

2. Office of Disease Prevention and Health Promotion. Reduce stroke deaths—HDS-03. Healthy People 2030. Accessed May 2026. https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/heart-disease-and-stroke/reduce-stroke-deaths-hds-03 [odphp.health.gov]

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

As we recognize National Women’s Health Week, it’s important to acknowledge well‑documented [PP1] disparities in vascula...
05/12/2026

As we recognize National Women’s Health Week, it’s important to acknowledge well‑documented [PP1] disparities in vascular care—particularly in arteriovenous (AV) access for women patients requiring hemodialysis.

· National and academic research has consistently shown that women are less likely than men to receive an arteriovenous fistula (AVF) as initial dialysis access and are more likely to start dialysis with catheters, which are associated with poorer outcomes. Studies note that smaller vessel diameters, differences in vascular anatomy, and delayed referral for access creation contribute to some of these disparities.¹,²
· Leading institutions have published findings indicating that anatomical factors—rather than suitability alone—often disproportionately limit AV access options for women, reinforcing the importance of innovation that accounts for real‑world patient differences.²
· Data from national registries and peer‑reviewed journals—including analyses supported by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH)—underscore that addressing AV access inequities requires intentional research, inclusive study design, and solutions developed with diverse vascular anatomies in mind.¹,³

At Humacyte, we are committed to understanding health inequities in vascular care and supporting innovation with the potential to improve access options for women and other historically underserved patient populations.

Advancing vascular health means designing care—and innovation—that works for everyone.

Learn more at www.humacyte.com

References:
1. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: Problems and solutions. Clin J Am Soc Nephrol. 2002;13(12):2979‑2985. https://doi.org/10.1111/j.1523-1755.2002.kid551.x
2. Lee T, Mokrzycki M, Moist L, et al. Standardized definitions for hemodialysis vascular access. Kidney Int. 2011;80(12):127‑145. https://pubmed.ncbi.nlm.nih.gov/21956188/
3. United States Renal Data System (USRDS). 2023 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. https://usrds-adr.niddk.nih.gov/2023



Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

National Nurses Week is here (May 6–12)!This National Nurses Week, we recognize the teams who help translate surgical ca...
05/11/2026

National Nurses Week is here (May 6–12)!

This National Nurses Week, we recognize the teams who help translate surgical care into healing, hope, and recovery for patients. We see the OR Circulators and Scrub Nurses who master the complexity and precision of the OR—ensuring instruments and life and limb saving treatments are ready the moment the surgeon calls for them. We recognize the Critical Care and Vascular Nurses whose vigilant monitoring and expert care guide patients through the vital days of recovery and back toward everyday life.

At Humacyte, we’re proud to support healthcare innovation that works alongside your expertise across the full continuum of care—every step of the way. Here’s to a week of gratitude, recognition, and well deserved appreciation.

Learn more about our innovations at https://humacyte.com



Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

On National Nurses Day, we’re honoring the nurses who help vascular surgery teams restore blood flow, protect limbs, and...
05/06/2026

On National Nurses Day, we’re honoring the nurses who help vascular surgery teams restore blood flow, protect limbs, and guide patients through complex procedures and recovery.

From pre op assessment and patient preparation to vascular suite readiness, post op monitoring, and follow up care, you bring technical excellence and steady guidance. You help make the right treatment options available for procedures and watch closely for the changes that matter most after surgery. Just as importantly, you educate patients and families on the care and recovery plans, and you advocate so concerns are heard quickly and care stays coordinated.

At Humacyte, we’re proud to support vascular surgery innovation designed to work alongside your clinical judgment across every step of care. Thank you for your precision in the OR suite, your vigilance in recovery, and the trust you build with every patient.

Learn more about our innovations at https://humacyte.com


Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

04/30/2026

Vascular injuries threaten both life and limb. Delayed intervention significantly increases the risk of tissue damage, fasciotomy, and amputation.(1) Published data show that 20% of patients arrive at the hospital > 5 hours after the injury, putting both life and limb at increased risk. (1)

Having and off the shelf and ready to use solution with minimal preparation supports rapid response once the patient arrives—when timing is already working against you.

Symvess® acellular tissue engineered vessel-tyod is the first and only FDA Approved, human-derived, bioengineered vessel approved for vascular injury repair. (2,3)

This Limb Loss and Limb Difference Awareness Month, we highlight the importance of readiness in extremity vascular injury repair.

Learn more about Symvess at www.Symvess.com

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE- Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

REFERENCES: 1. Alarhayem A, et al. Impact of time to repair in outcomes in patients with lower extremity arterial injuries. J Vasc Surg. 2019; 69: 1519-1523. 2. Symvess U.S. Prescribing Information. Durham, NC. Humacyte Global, Inc. 3. Dahl S, et al. Readily available tissue-engineered vascular grafts. Sci Transl Med. 2011 Feb 2;3(68):68ra9.



Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc.
All Rights Reserved. US-SYM-000338

Address

2525 NC-54
Durham, NC

Telephone

+19193139633

Website

Alerts

Be the first to know and let us send you an email when Humacyte posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Humacyte:

Shortcuts

Share

Category